| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V71466 | (1α,1'S,4β)-Lanabecestat ((1α,1'S,4β)-AZD3293; (1α,1'S,4β)-LY3314814) | 1384082-96-5 | (1α,1'S,4β)-Lanabecestat ((1α,1'S,4β)-AZD3293) is a less active isomer of Lanabecestat. |
|
V117352 | BACE-1/Mpro-IN-1 | BACE-1/Mpro-IN-1 is a dual inhibitor that can simultaneously inhibit BACE-1 (IC50 = 0.26 μM) and SARS-CoV-2 Mpro (IC50 = 0.91 μM) and can easily cross the blood-brain barrier. | |
|
V71449 | BACE1-IN-13 | 1397683-26-9 | BACE1-IN-13 (Compound 36) is an orally bioactive BACE1 inhibitor (antagonist) with IC50 of 2.9 nM. |
|
V71459 | BACE1-IN-6 | 2079945-75-6 | BACE1-IN-6 is a BACE1 inhibitor (antagonist) with IC50 of 1.5 nM. |
|
V115512 | CTS-21166 | 1226777-95-2 | CTS-21166 is a BACE1 inhibitor that can cross the blood-brain barrier and is effective when taken orally. |
|
V71446 | Elenbecestat (E2609) | 1388651-30-6 | Elenbecestat (E2609) is a potent, orally bioactive, CNS-penetrating BACE-1 inhibitor. |
|
V71457 | Kushenol C | 99119-73-0 | Kushenol C is extracted from Sophora flavescens root and has anti-inflammatory and antioxidant properties. |
|
V3023 | LX2343 | 333745-53-2 | LX2343, discovered by high throughout screening, is a small molecule compound that can effectively reverse the streptozocin (STZ)-induced neuronal apoptosis and tau hyperphosphorylation in vitro and in vivo. |
|
V1313 | LY2811376 | 1194044-20-6 | LY2811376 (LY-2811376; LY 2811376) is a novel, potent, selective and the first orally bioavailable non-peptidic β-secretase (BACE1) inhibitor with the potential for the treatment of Alzheimers Disease (AD). |
|
V71447 | LY2886721 hydrochloride | 1262036-49-6 | LY2886721 HCl is a specific, orally bioactive beta-amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor (antagonist) with IC50 of 20.3 nM against recombinant human BACE1. |
|
V71455 | β-Secretase Inhibitor II | 263563-09-3 | β-Secretase Inhibitor II is a β-Secretase inhibitor. |
|
V2792 | Verubecestat (MK-8931) | 1286770-55-5 | Verubecestat (formerly known as MK8931; SCH-900931) is a beta-secretase 1 and BACE1 inhibitor that is in Phase 3 clinical trial for treatment of Alzheimer's disease. |
|
V3813 | Atabecestat (JNJ-54861911) | 1200493-78-2 | Atabecestat (formerly known as JNJ-54861911) is a novel potent, oral, and brain-penetrantBACE1 inhibitor that inhibits β-site amyloid precursor protein cleaving enzyme 1 (BACE1), an enzyme up-regulated in Alzheimer's disease. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
